AASLD

09/12/2025

We are thrilled to announce the 2025 Distinguished Award recipients!

Each year, AASLD proudly honors the individuals whose vision, leadership, and dedication drive the future of . AASLD’s Distinguished Awards are the highest honors we can bestow on those who exemplify excellence in service, mentorship, scientific advancement, and advocacy.

Our 2025 Distinguished Awards recipients have made lasting contributions that extend far beyond their own work by building stronger communities of practice, advancing lifesaving research, and improving the lives of those affected by .

Learn more about each recipient and their remarkable work: https://bit.ly/4giq0SS.

09/11/2025

📗Co-Editors Elliot B. Tapper, MD, FAASLD and Carmen Chak-Lui Wong, PhD share the latest highlights from including a state-of-the-art review on , and articles on carbon ion radiotherapy, new HCC treatments, the current clinical uses of artificial liver support systems, and more!

View the latest issue online: https://journals.lww.com/hepcomm.

https://www.youtube.com/watch?v=Q11jx92T7zY&t=3s

Editor-in-Chief of Clinical Research, Elliot B. Tapper, MD, FAASLD and Editor-in-Chief of Basic Science Carmen Chak-Lui Wong, PhD share the latest highlights...

09/10/2025

The birth-dose vaccine prevents chronic infections, liver disease, and even liver cancer later in life. Next week, CDC will be reconsidering the recommendation for the universal hepatitis B birth dose. Without strong national guidance, thousands of infants could be left unprotected and at-risk.

ACT NOW: Tell Congress to protect access to this life-saving vaccine and lifelong . Visit our Policy Action Center to contact your representatives today: https://www.aasld.org/aasld-policy-action-center #/

09/10/2025

Step into The Park @ TLM, where science meets community!

Network with 9,000+ hepatology pros from around the world, join topic-driven chats at SIGs in the Park, relax and recharge in the Park @ TLM, or show off your skills at the second annual Pickleball Tournament. TLM is where expertise expands, networks strengthen, and collaboration thrives. https://bit.ly/41zAcAr

09/09/2025

🗣️ Share your thoughts!

Now through Sept. 19, is accepting public comments for the proposed recommendations in the AASLD Practice Guideline on Adult : Diagnosis and Post-Transplant Management of Non-Graft-Related Complications. https://bit.ly/3V6g59

09/09/2025

FINAL REMINDER: This is your last chance for up to $36,000 in Innovation Award funding through the AASLD Project Portal. Submissions close tomorrow, 9/10. Don’t miss your chance to turn your idea into impact. 🔗 https://aasldprograms.secure-platform.com/site

09/05/2025

Did you know? Liver cancer prevention can start at birth.

The vaccine is more than a shot. It's the first step to protecting newborns and preventing .

Use Hepatitis B Foundation's toolkit to spread the word! Learn more here: https://bit.ly/4n9pyZm

Universal infant vaccine birth dose saves thousands of lives: A response from the Hepatitis B Foundation | Please read more here

09/04/2025

📙 Read the latest Policy Corner from !

The evolution of liver allocation is moving beyond geography. Continuous Distribution introduces a composite scoring system that prioritizes urgency, equity, and transparency—ensuring organs go to those who need them most. https://bit.ly/45I8i6o

09/03/2025

🗳️ It’s election season!

AASLD members are invited to vote in the 2026 AASLD General Election and the SIG Steering Committee election.

✅ Eligible members will receive an email from Election Runner with a unique voter ID/key and direct ballot link. Please do not share.
🗓️ Voting is now open through Wednesday, Sept. 24, at 11:59 p.m. EDT.
📢 Results will be announced in mid-October.

Learn more at aasld.org/aasld-elections.

09/03/2025

Mother-to-child transmission (MTCT) is the main way spreads worldwide. We already have tools to prevent it, but they don't reach everyone. New innovations and accessible approaches can help close the gap, especially in resource-limited settings.

Attend this webinar to:
✅ Understand standards of care, including AASLD guidelines
✅ Identify recommended antiviral therapies in pregnancy
✅ Review insights from the latest JAMA clinical trial on tenofovir disoproxil fumarate (TDF)

Register now: https://bit.ly/462Dg9M

09/03/2025

One week left! Don’t miss your chance to shape the future of liver health. AASLD’s Project Portal is your place to submit innovative ideas that align with our strategic priorities and move the field forward. Submit by September 10 and your project could receive up to $36,000 in Innovation Award funding, thanks to a generous anonymous donor.

There’s still time to bring your idea to life! Submit now: https://aasldprograms.secure-platform.com/site

09/02/2025

As the leading organization representing clinicians and researchers, is committed to advancing evidence-based policies that protect liver health. Vaccination against at birth is one of the most effective tools we have to prevent lifelong infection and reduce liver disease, including liver cancer.

The CDC’s universal hepatitis B birth-dose recommendation is a proven public health success. Since its adoption in 1991:

1. Infant hepatitis B infections in the U.S. have declined by 95%
2. More than 90,000 deaths have been prevented
3. Ranked among the most impactful childhood immunizations
4. A recent study also found that hepatitis B vaccination has prevented over 6 million infections and nearly 1 million hospitalizations in less than 30 years.

AASLD stands ready to work with legislators, the Administration, and public health partners to continue the incredible progress achieved through hepatitis B vaccination.